ReviewEClinicalMedicine2026
Challenges and possible solutions towards reaching global cervical cancer elimination.
Review in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Regional Pathology-Detection Trends in High-Grade Cervical Lesions and Cervical Squamous Cell Carcinoma Among Women Aged 40-69 Years in Northern Norway, 1998-2025.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a leading cause of cancer-related mortality among women, despite being largely preventable through Human Papillomavirus (HPV) vaccination, HPV screening, and treatment. The World Health Organization (WHO) has called for global elimination of cervical cancer. While progress has been made in the worldwide implementation of preventive measures, the global uptake (particularly of HPV-based screening) lags behind. However, a major advance is the increased supply of HPV vaccines, propelled partly by the shift to one-dose vaccine schedules, which presents new opportunities for faster cervical cancer elimination using expanded HPV vaccination strategies such as gender-neutral vaccination, catch-up vaccination, and concomitant vaccination and screening. Another major advance is the WHO target product profile that specifies that only the 8 most important types of HPV must be screened for, which greatly improves the specificity and feasibility of HPV-based screening. This article outlines the key challenges, highlights successful examples of innovative strategies, and proposes evidence-based next steps, including specific actions on global prioritization, real-time monitoring, innovation, and equity-driven action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.